Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003
- PMID: 15673726
- PMCID: PMC547329
- DOI: 10.1128/AAC.49.2.512-517.2005
Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003
Abstract
The susceptibilities of nonduplicate isolates to six antifungal agents were determined for 391 blood isolates of seven Candida species, 70 clinical isolates (from blood or cerebrospinal fluid) of Cryptococcus neoformans, and 96 clinical isolates of four Aspergillus species, which were collected in seven different hospitals in Taiwan (as part of the 2003 program of the study group Surveillance of Multicenter Antimicrobial Resistance in Taiwan). All isolates of Candida species other than C. glabrata and C. krusei were susceptible to fluconazole. Among the 59 C. glabrata isolates, 16 (27%) were not susceptible to fluconazole, and all were dose-dependently susceptible or resistant to itraconazole. For three (5.1%) C. glabrata isolates, voriconazole MICs were 2 to 4 microg/ml, and for all other Candida species isolates, voriconazole MICs were </=0.5 microg/ml. The proportions of isolates for which amphotericin B MICs were >/=2 microg/ml were 100% (3 isolates) for C. krusei, 11% (23 of 207 isolates) for Candida albicans, 3.0% (2 of 67 isolates) for Candida tropicalis, 20% (12 of 59 isolates) for C. glabrata, and 0% for both Candida parapsilosis and Candida lusitaniae. For three (4%) Cryptococcus neoformans isolates, fluconazole MICs were >/=16 microg/ml, and two (3%) isolates were not inhibited by 1 mug of amphotericin B/ml. For four (4.2%) of the Aspergillus isolates, itraconazole MICs were 8 microg/ml. Aspergillus flavus was less susceptible to amphotericin B, with the MICs at which 50% (1 microg/ml) and 90% (2 microg/ml) nsrsid417869\delrsid7301351 of isolates were inhibited being twofold greater than those for Aspergillus fumigatus and Aspergillus niger. All Aspergillus isolates were inhibited by </=1 microg of voriconazole/ml, including isolates with increased resistance to amphotericin B and itraconazole. This study revealed the emergence in Taiwan of decreased susceptibilities of Candida species to amphotericin B and of C. neoformans to fluconazole and amphotericin B. Voriconazole was the most potent agent against the fungal isolates tested, including fluconazole- and amphotericin B-nonsusceptible strains.
Figures


Similar articles
-
Susceptibilities to amphotericin B and fluconazole of Candida species in Taiwan Surveillance of Antimicrobial Resistance of Yeasts 2006.Diagn Microbiol Infect Dis. 2008 Jun;61(2):175-80. doi: 10.1016/j.diagmicrobio.2008.01.011. Epub 2008 Mar 4. Diagn Microbiol Infect Dis. 2008. PMID: 18304773
-
In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.Int J Antimicrob Agents. 2005 Apr;25(4):321-8. doi: 10.1016/j.ijantimicag.2004.11.010. Int J Antimicrob Agents. 2005. PMID: 15784312
-
In vitro susceptibilities of bloodstream isolates of Candida spp.: results from a multicenter active surveillance program in Andalusia.Enferm Infecc Microbiol Clin. 2009 Nov;27(9):518-22. doi: 10.1016/j.eimc.2008.09.013. Epub 2009 May 23. Enferm Infecc Microbiol Clin. 2009. PMID: 19477048
-
Antifungal drug resistance in pathogenic fungi.Med Mycol. 1998;36 Suppl 1:119-28. Med Mycol. 1998. PMID: 9988500 Review.
-
Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.J Hosp Infect. 2002 Apr;50(4):243-60. doi: 10.1053/jhin.2001.1151. J Hosp Infect. 2002. PMID: 12014897 Review.
Cited by
-
Epidemiology of invasive candidiasis: a persistent public health problem.Clin Microbiol Rev. 2007 Jan;20(1):133-63. doi: 10.1128/CMR.00029-06. Clin Microbiol Rev. 2007. PMID: 17223626 Free PMC article. Review.
-
Efflux-mediated antifungal drug resistance.Clin Microbiol Rev. 2009 Apr;22(2):291-321, Table of Contents. doi: 10.1128/CMR.00051-08. Clin Microbiol Rev. 2009. PMID: 19366916 Free PMC article. Review.
-
Culture-positive invasive aspergillosis in a medical center in Taiwan, 2000-2009.Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1319-26. doi: 10.1007/s10096-011-1445-1. Epub 2011 Oct 14. Eur J Clin Microbiol Infect Dis. 2012. PMID: 21997774
-
The trend of susceptibilities to amphotericin B and fluconazole of Candida species from 1999 to 2002 in Taiwan.BMC Infect Dis. 2005 Nov 3;5:99. doi: 10.1186/1471-2334-5-99. BMC Infect Dis. 2005. PMID: 16266438 Free PMC article.
-
Combination efficacy of voriconazole and amphotericin B in the experimental disease in immunodeficient mice caused by fluconazole-resistant Cryptococcus neoformans.Mycopathologia. 2011 Apr;171(4):261-6. doi: 10.1007/s11046-010-9375-5. Epub 2010 Oct 24. Mycopathologia. 2011. PMID: 20972836
References
-
- Abraham, O. C., E. K. Manavathu, J. L. Cutright, and P. H. Chandrasekar. 1999. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B. Diagn. Microbiol. Infect. Dis. 33:7-11. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical